Yonsei, REPUBLIC OF KOREA - 30 Aug `18Investigation on the Expression of HMGB1

Official Title: The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity

In Brief: Vitiligo is an acquired depigmented disorder that causes white spots on the skin due to the loss of melanocytes. It is a common disease which accounts for 0.5-1% of the whole population. It is a refractory skin disease with 25-50 thousand patients in Korea. And it is often caused in the exposed areas of the patient, causing a great deal of mental and social dysfunction in the patient's life, and may lead to suicide attempts.

Ages Eligible: 19 Years and older

Start Date: August 30, 2018

Completion Date (estimated): August 29, 2020

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT03741738

Location: Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea, 03722

Contact: To learn more about this study, you or your doctor may contact Sang Ho Oh, MD, PhD by phone +82 2 2228 2080 or email oddung93@yuhs.ac. Please refer to this study by its NCT number.

Back

FAQOther Questions

  • Can Ginkgo Biloba help with vitiligo?

    Ginkgo Biloba seems to be a simple, safe, inexpensive and fairly effective therapy for vitiligo. It is mostly effective in halting the progression of the disease. It can also sp...

  • Who is prone to vitiligo?

    Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...

  • Is it Bitiligo? Vitaligo? Veteligo?

    There are so many different ways that people try and spell or even pronounce Vitiligo.  Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vita...